hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06362850, orgStudyIdInfo id: 1253/2023, briefTitle: Tele-Support for Emergency Medical Technicians, acronym: POHCA, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-08, primaryCompletionDateStruct date: 2024-04-18, completionDateStruct date: 2024-12-01, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Medical University of Vienna, class: OTHER, collaborators name: Ludwig Boltzmann Institute Digital Health and Patient Safety, descriptionModule briefSummary: In this manikin-based simulation study the impact of tele-support during a simulated pediatric out-of-hospital cardiac arrest scenario on emergency medical technicians' guideline adherence, on gaze behavior as well as on performance of resuscitation management and cognitive load will be analyzed., conditionsModule conditions: Cardiac Arrest, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: In a manikin-based simulation study, the participants will be randomized to either performing the scenario with tele-support or without tele-support (80 participants 40 groups, 20 groups with tele-support, 20 groups without tele-support)., primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Tele-support, outcomesModule primaryOutcomes measure: guideline adherence, secondaryOutcomes measure: gaze behavior, secondaryOutcomes measure: teamwork performance, secondaryOutcomes measure: cognitive load, secondaryOutcomes measure: Performance of cardiopulmonary resuscitation, secondaryOutcomes measure: Technical feasibility, secondaryOutcomes measure: Usability, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Department of Anesthesia, General Intensive Care and Pain Management,Medical University of Vienna, status: RECRUITING, city: Vienna, zip: 1090, country: Austria, contacts name: Christina Hafner, MD, PhD, role: CONTACT, phone: 004314040041020, email: christina.hafner@meduniwien.ac.at, geoPoint lat: 48.20849, lon: 16.37208, hasResults: False
protocolSection identificationModule nctId: NCT06362824, orgStudyIdInfo id: 2094138, briefTitle: Promoting Physical Activity in Older Hispanic/Latino(a) Adults, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2028-09-30, completionDateStruct date: 2029-09-30, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: Kaiser Permanente, class: OTHER, collaborators name: University of California, San Diego, descriptionModule briefSummary: In this randomized controlled trial, study staff will randomize 130 Hispanic/Latino adults without dementia and over age 55 from Southern California to either the culturally adapted De Pie physical activity intervention or an active comparison program focusing on general brain health topics. The purpose of this study is to determine if 12 weeks of the culturally adapted and fully remote De Pie y a Movernos intervention improves self-efficacy, habit strength, social support, and enjoyment for physical activity (PA), thus promoting adherence to moderate-intensity physical activity (MIPA) guidelines (150 minutes/week)., conditionsModule conditions: Sedentary Behavior, conditions: Physical Inactivity, conditions: Alzheimer Disease, Protection Against, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 130, type: ESTIMATED, armsInterventionsModule interventions name: De Pie Intervention, interventions name: Active Comparison Group: Healthy Actions And Lifestyles To Avoid Dementia (HALT-AD), outcomesModule primaryOutcomes measure: Change in Moderate Intensity Physical Activity (MIPA) minutes/day, secondaryOutcomes measure: Meet MIPA guidelines of 150 minutes physical activity per week, eligibilityModule sex: ALL, minimumAge: 55 Years, maximumAge: 89 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of California San Diego, city: San Diego, state: California, zip: 92093, country: United States, contacts name: Zvinka Z Zlatar, PhD, role: CONTACT, email: zzlatar@health.ucsd.edu, contacts name: Zvinka Z Zlatar, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 32.71533, lon: -117.15726, hasResults: False
protocolSection identificationModule nctId: NCT06362811, orgStudyIdInfo id: 483730, briefTitle: Assessment of Efficacy of Sacral Erector Spinae Plane Block for Postoperative Analgesia in Pediatric Rectal Biopsies, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-01-01, primaryCompletionDateStruct date: 2023-12-31, completionDateStruct date: 2023-12-31, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Istanbul University, class: OTHER, descriptionModule briefSummary: The purpose of this study is to evaluate how sacral erector spinae block changed the postoperative analgesia requirements in pediatric patients undergoing rectal biopsies under general anesthesia., conditionsModule conditions: Analgesia, conditions: Pain, Acute, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 48, type: ACTUAL, armsInterventionsModule interventions name: Sacral Erector Spinae Plane Block, outcomesModule primaryOutcomes measure: Postoperative pain scores, primaryOutcomes measure: Analgesia requirement, secondaryOutcomes measure: Complications, eligibilityModule sex: ALL, minimumAge: 1 Day, maximumAge: 5 Years, stdAges: CHILD, contactsLocationsModule locations facility: Istanbul University Cerrahpasa, city: Istanbul, zip: 34098, country: Turkey, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06362772, orgStudyIdInfo id: MR-36-24-010944, briefTitle: Clinical Efficacy of 125I Seed Implantation in the Treatment of Refractory Differentiated Thyroid Cancer, statusModule overallStatus: COMPLETED, startDateStruct date: 2015-01-01, primaryCompletionDateStruct date: 2022-02-01, completionDateStruct date: 2023-04-01, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Jiangxi Provincial Cancer Hospital, class: OTHER, descriptionModule briefSummary: A retrospective analysis was conducted on RAIR-DTC patients who underwent radioactive 125I seed implantation from January 2015 to February 2022 at Jiangxi Cancer Hospital. Prescription dose: 80\~120 Gy. All cases were followed up at 1, 3, and 5 months postoperatively to monitor changes in tumor size, serum thyroglobulin (Tg), and serum anti-thyroglobulin antibody levels in thyrotropin-inhibited states, pain scores, and postoperative adverse reactions. The data were processed and analyzed using IBM SPSS 26.0. Pairwise comparisons were conducted using the Wilcoxon signed-rank test, and a p-value of less than 0.05 indicated statistical significance., conditionsModule conditions: Thyroid Neoplasms, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 36, type: ACTUAL, armsInterventionsModule interventions name: Iodine-125 brachytherapy, outcomesModule primaryOutcomes measure: Tumor size, primaryOutcomes measure: Serological assessment, primaryOutcomes measure: Pain score, primaryOutcomes measure: Adverse event, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06362759, orgStudyIdInfo id: TOUR006-C01, briefTitle: A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP, acronym: TRANQUILITY, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-05, completionDateStruct date: 2026-02, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Tourmaline Bio, Inc., class: INDUSTRY, descriptionModule briefSummary: This study will evaluate the safety, tolerability, pharmacokinetics, and CRP-lowering effect of quarterly and monthly subcutaneous administration of TOUR006 in participants with chronic kidney disease and elevated hs-CRP., conditionsModule conditions: Chronic Kidney Diseases, conditions: Chronic Kidney Insufficiency, conditions: Chronic Renal Diseases, conditions: Chronic Renal Insufficiency, conditions: Kidney Insufficiency, Chronic, conditions: C-Reactive Protein, conditions: High Sensitivity C-Reactive Protein, conditions: Hs-CRP, conditions: hsCRP, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule interventions name: TOUR006 - 50 MG, interventions name: TOUR006 - 25 MG, interventions name: TOUR006 - 15 MG, interventions name: Placebo, outcomesModule primaryOutcomes measure: Evaluate the effects of TOUR006 compared with placebo on hs-CRP, secondaryOutcomes measure: Evaluate the effects of TOUR006 compared with placebo on hs-CRP, secondaryOutcomes measure: Evaluate the pharmacokinetics by measuring serum concentrations of TOUR006, secondaryOutcomes measure: Evaluate the safety and tolerability of TOUR006 in participants with elevated cardiovascular risk and CKD, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06362720, orgStudyIdInfo id: 720/2566(IRB2), briefTitle: The Comparison the CMV Infection and Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation Between Standard Regimen, Methotrexate Plus Cyclosporin A, and Post-transplant Cyclophosphamide-based Regimen, acronym: CMV, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2024-10-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Siriraj Hospital, class: OTHER, descriptionModule briefSummary: The goal of this observational study is to compare the CMV infection and reactivation after allogeneic hematopoietic stem cell transplantation Between Standard Regimen, Methotrexate plus Cyclosporin A, and Post-transplant Cyclophosphamide-based Regimen. The main questions it aims to answer are:* How do CMV infection and reactivation differ between Allo-SCT patients who received a standard regimen versus those who received a Post-transplant Cyclophosphamide-based regimen?* progression-free survival, Median overall survival, cumulative incidence of relapse, non-relapsed mortality (NRM) and GvHD at 2 years after Allo-SCT* The impact of CMV infection and CMV reactivation on progression-free survival, overall survival, and NRM* Averse events of GVHD prophylaxis medication Participants will be collected the data of treatment and treatment response during transplant until 2 years after transplant from hospital medical record., conditionsModule conditions: CMV Infection or Reactivation After Allogenic HSCT, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: RETROSPECTIVE, enrollmentInfo count: 158, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Number of participants with CMV infection and reactivation, secondaryOutcomes measure: progression-free survival, secondaryOutcomes measure: Median overall survival, secondaryOutcomes measure: cumulative incidence of relapse, secondaryOutcomes measure: non-relapsed mortality, secondaryOutcomes measure: GvHD, secondaryOutcomes measure: Averse events, eligibilityModule sex: ALL, minimumAge: 15 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06362694, orgStudyIdInfo id: 34, briefTitle: Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-25, primaryCompletionDateStruct date: 2026-03-25, completionDateStruct date: 2026-06-25, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Saint Petersburg State University, Russia, class: OTHER, descriptionModule briefSummary: This pilot phase 2 study evaluates the effectiveness and safety of the Rechallenge concept in patients with BRAF-positive anaplastic thyroid cancer after progression on anti-BRAF therapy. Patients with BRAF-positive anaplastic thyroid cancer who were previously treated with dabrafenib and trametinib (with a clinical or objective response at the start of treatment) and later with tumor progression during anti-BRAF therapy and subsequent lines of chemotherapy are scheduled to undergo targeted therapy (repeated administration of dabrafenib and trametinib in standard doses) and evaluate the outcomes according to the primary and secondary endpoints., conditionsModule conditions: Anaplastic Thyroid Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: Dabrafenib + Trametinib, outcomesModule primaryOutcomes measure: Objective response rate, primaryOutcomes measure: Progression-Free Survival, primaryOutcomes measure: Safety and Tolerability assessment (Incidence of Treatment-Emergent Adverse Events), secondaryOutcomes measure: Overall survival, secondaryOutcomes measure: The assessment of conversion to resectability, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Saint Petersburg State University Hospital, status: RECRUITING, city: Saint Petersburg, zip: 190020, country: Russian Federation, contacts name: Ernest Dzhelialov, role: CONTACT, phone: +7(911)134-50-44, email: ernest.dzhelialov@gmail.com, geoPoint lat: 59.93863, lon: 30.31413, hasResults: False
protocolSection identificationModule nctId: NCT06362681, orgStudyIdInfo id: CF-2023-I-13, briefTitle: Effects of Different Remineralization Agents on Molar Incisor Hypomineralization Defects: a Randomized Clinical Study, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2024-06-30, completionDateStruct date: 2026-03-30, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Universidad Nacional Autonoma de Mexico, class: OTHER, descriptionModule briefSummary: The aim of this study was to present a comparative evaluation of the long-term efficacy of fluoride varnish( Flúor protector), Clinpro™ White Varnish and pastes containing CPP-ACP in the remineralization of creamy-white and yellow brown defects in incisors and permanent first molars with Molar Incisor Hypomineralization (MIH) in schoolchildren 6-12 years-old in Mexico., conditionsModule conditions: Molar Incisor Hypomineralization, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: SINGLE_GROUP, interventionModelDescription: The children will be randomly divided into the experiment groups: control (oral hygiene motivation only), fluoride varnish, clinpro white Varnish and pastes containing CPP-ACP and followed up for 24 months., primaryPurpose: PREVENTION, maskingInfo masking: QUADRUPLE, maskingDescription: using a block randomization technique in which a computer-generated sequence would be used to assign each participant to a particular group in the allocation ratio of 1:1., whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Fluoride, outcomesModule primaryOutcomes measure: Mineral Density, eligibilityModule sex: ALL, minimumAge: 6 Years, maximumAge: 12 Years, stdAges: CHILD, contactsLocationsModule locations facility: Alvaro Garcia Pérez, status: RECRUITING, city: San Pedro Apatlaco, state: Morelos, country: Mexico, geoPoint lat: 18.79306, lon: -98.95972, hasResults: False
protocolSection identificationModule nctId: NCT06362668, orgStudyIdInfo id: RCV-0006-EU, briefTitle: EU Sites: Fluid Management of Acute Decompensated Heart Failure With Reprieve Decongestion Management System (FASTR-EU), acronym: FASTR-EU, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-09, primaryCompletionDateStruct date: 2024-10-01, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Reprieve Cardiovascular, Inc, class: INDUSTRY, descriptionModule briefSummary: The objective of this study is to prospectively compare decongestive therapy administered by the Reprieve DMS system to Optimal Diuretic Therapy (ODT) in the treatment of patients diagnosed with acute decompensated heart failure (ADHF). The main objective is to determine if the Reprieve DMS is non-inferior to state-of-the-art urine sodium guided aggressive diuretic titration in two European HF centers of excellence., conditionsModule conditions: Acute Decompensated Heart Failure, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Reprieve Decongestion Management System, interventions name: Diuretic (furosemide, bumetanide, torsemide, hydrochlorothiazide, and/or acetazolamide), outcomesModule primaryOutcomes measure: Total sodium loss (in mmol of sodium) per 24 hours, primaryOutcomes measure: Comparison of occurrence of composite endpoint comprised of clinically significant acute kidney injury, severe electrolyte abnormality, or symptomatic hypotension or hypertensive emergency., secondaryOutcomes measure: Total net fluid volume loss (difference between urine output volume and fluid input volume) per 24 hours, secondaryOutcomes measure: Weight loss per 24 hours at end of randomized therapy, secondaryOutcomes measure: Time on IV loop diuretic, secondaryOutcomes measure: Number of participants with ≥ 0.3 mg/dL increase in serum creatinine, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University Medical Center Groningen, city: Groningen, country: Netherlands, contacts name: Kevin Damman, MD, role: CONTACT, geoPoint lat: 53.21917, lon: 6.56667, locations facility: Wroclaw Medical University, city: Wrocław, country: Poland, contacts name: Jan Biegus, MD, role: CONTACT, geoPoint lat: 51.1, lon: 17.03333, hasResults: False
protocolSection identificationModule nctId: NCT06362616, orgStudyIdInfo id: N23PBD, briefTitle: Preoperative Accelerated Partial Breast Irradiation in Patients With Locally Recurrent or Second Primary Breast Cancer, acronym: PAPBI-3, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-12, primaryCompletionDateStruct date: 2026-10-11, completionDateStruct date: 2027-04-11, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: The Netherlands Cancer Institute, class: OTHER, descriptionModule briefSummary: This study evaluates the acute toxicity and feasibility of repeat breast conserving therapy with preoperative accelerated partial breast re-irradiation (PAPBI) in female patients aged 51 years or older with ipsilateral recurrent or second primary low-risk breast cancer., conditionsModule conditions: Breast Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 31, type: ESTIMATED, armsInterventionsModule interventions name: Preoperative accelerated partial breast irradiation, interventions name: Breast conserving surgery, interventions name: Sentinel node procedure, interventions name: Biopsy track removal, outcomesModule primaryOutcomes measure: Acute post-treatment toxicity, secondaryOutcomes measure: Fibrosis/induration, secondaryOutcomes measure: Patient-reported Outcome Measures (PROMS): EORTC Quality of Life Questionnaire (QLQ)-C30, secondaryOutcomes measure: Patient-reported Outcome Measures (PROMS): EORTC QLQ-BR23, secondaryOutcomes measure: Patient-reported Outcome Measures (PROMS): Patient's Questionnaire Cosmesis, secondaryOutcomes measure: Cosmetic outcome according to the BCCT.core software program, eligibilityModule sex: FEMALE, minimumAge: 51 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The Netherlands Cancer Institute, status: RECRUITING, city: Amsterdam, zip: 1066CX, country: Netherlands, contacts name: Astrid Scholten, MD PhD, role: CONTACT, phone: +31205129111, email: a.scholten@nki.nl, geoPoint lat: 52.37403, lon: 4.88969, hasResults: False
protocolSection identificationModule nctId: NCT06362603, orgStudyIdInfo id: FB2022NIH, briefTitle: [Trial of device that is not approved or cleared by the U.S. FDA], statusModule overallStatus: WITHHELD, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: [Redacted], hasResults: False
protocolSection identificationModule nctId: NCT06362590, orgStudyIdInfo id: LV-SPIND-001, briefTitle: Expanded Access Use of Ladiratuzumab Vedotin in Advanced Solid Tumors, statusModule overallStatus: AVAILABLE, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Seagen Inc., class: INDUSTRY, descriptionModule briefSummary: The purpose of this study is to provide the option of Ladiratuzumab Vedotin treatment to eligible patients in studies SGNLVA-005., designModule studyType: EXPANDED_ACCESS, armsInterventionsModule interventions name: ladiratuzumab vedotin, eligibilityModule stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False